BioCentury
ARTICLE | Clinical News

AT13387: Phase I data

May 28, 2012 7:00 AM UTC

Data from 53 evaluable patients in a open-label, dose-escalating, U.S. Phase I trial showed that the MTD of once-weekly IV AT13387 was 260 mg/m 2. AT13387 produced 1 partial response in a patient with...